Alto Neuroscience (ANRO) Stock Price, News & Analysis

Company Overview

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Key Stats

• Today's Range: $4.31 to $4.65
• 50-Day Range: $3.64 to $4.84
• 52-Week Range: $3.56 to $24.00
• Volume: 204,596 shs
• Average Volume: 221,038 shs
• Market Capitalization: $123.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Moderate Buy

Alto Neuroscience Stock Analysis - MarketRank™

Alto Neuroscience scored higher than 52% of companies evaluated by MarketBeat, and ranked 572nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alto Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Alto Neuroscience has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alto Neuroscience are expected to grow in the coming year, from ($2.54) to ($2.39) per share.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.34% of the float of Alto Neuroscience has been sold short.

Short Interest Ratio / Days to Cover

Alto Neuroscience has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Alto Neuroscience has recently decreased by 2.46%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alto Neuroscience does not currently pay a dividend.

Dividend Growth

Alto Neuroscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.34% of the float of Alto Neuroscience has been sold short.

Short Interest Ratio / Days to Cover

Alto Neuroscience has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Alto Neuroscience has recently decreased by 2.46%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for ANRO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alto Neuroscience insiders have not sold or bought any company stock.

ANRO Stock Analysis - Frequently Asked Questions

How have ANRO shares performed this year?

Alto Neuroscience's stock was trading at $4.23 at the beginning of 2025. Since then, ANRO stock has increased by 8.6% and is now trading at $4.5950.
View the best growth stocks for 2025 here.

How were Alto Neuroscience's earnings last quarter?

Alto Neuroscience, Inc. (NYSE:ANRO) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.62) EPS for the quarter, topping analysts' consensus estimates of ($0.67) by $0.05.

When did Alto Neuroscience IPO?

Alto Neuroscience (ANRO) raised $129 million in an IPO on Friday, February 2nd 2024. The company issued 8,040,000 shares at $16.00 per share.

How do I buy shares of Alto Neuroscience?

Shares of ANRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alto Neuroscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alto Neuroscience investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 1/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:ANRO
• Previous Symbol: NYSE:ANRO
• CUSIP: N/A
• CIK: 1999480
• Web: www.altoneuroscience.com
• Phone: (650) 200-0412
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $20.00
• High Stock Price Target: $43.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +335.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-36,310,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -49.28%
• Return on Assets: -33.52%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 13.10
• Quick Ratio: 13.09

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 26,970,000
• Free Float: N/A
• Market Cap: $123.93 million
• Optionable: N/A
• Beta: N/A